Dyne Therapeutics (DYN) Accumulated Expenses (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Accumulated Expenses of $46.4 million for Q2 2026, up 106.46% year-over-year from $22.5 million in Q2 2025, and up 58.7% quarter-over-quarter from $29.2 million in Q1 2026.
Dyne Therapeutics (DYN) Accumulated Expenses (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Accumulated Expenses for 8 consecutive years, with $46.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Accumulated Expenses rose 106.46% year-over-year to $46.4 million; the TTM figure through Jun 2026 stood at $46.4 million (up 106.46% YoY), while the FY2025 annual figure was $37.5 million, up 21.73% from the prior year.
- Accumulated Expenses grew to $46.4 million in Q2 2026 per DYN's latest filing, from $29.2 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $46.4 million in Q2 2026 and bottomed at $8.2 million in Q1 2023.
- Historically, Accumulated Expenses has averaged $23.6 million across 5 years, with a median of $22.1 million in 2025.
- Annual changes were most pronounced in 2023 — Accumulated Expenses plunged 38.72% — and 2025, when it soared 109.29%.
- Dyne Therapeutics' Accumulated Expenses stood at $18.2 million in 2022, then increased by 28.65% to $23.4 million in 2023, then jumped by 31.6% to $30.8 million in 2024, then gained by 21.73% to $37.5 million in 2025, then advanced by 23.47% to $46.4 million in 2026.
- Business Quant data shows DYN's Accumulated Expenses at $46.4 million in Q2 2026, $29.2 million in Q1 2026, and $37.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.36 Mn |
| Mar 31, 2026 | 29.21 Mn |
| Dec 31, 2025 | 37.55 Mn |
| Sep 30, 2025 | 42.75 Mn |
| Jun 30, 2025 | 22.45 Mn |
| Mar 31, 2025 | 21.75 Mn |
| Dec 31, 2024 | 30.85 Mn |
| Sep 30, 2024 | 32.29 Mn |
| Jun 30, 2024 | 23.09 Mn |
| Mar 31, 2024 | 10.39 Mn |
| Dec 31, 2023 | 23.44 Mn |
| Sep 30, 2023 | 21.43 Mn |
| Jun 30, 2023 | 12.78 Mn |
| Mar 31, 2023 | 8.17 Mn |
| Dec 31, 2022 | 18.22 Mn |
| Sep 30, 2022 | 17.83 Mn |
| Jun 30, 2022 | 13.16 Mn |
| Mar 31, 2022 | 13.34 Mn |
| Dec 31, 2021 | 20.80 Mn |
| Sep 30, 2021 | 11.67 Mn |